热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　瑞银发布研究报告称，维持和黄医药（00013）“买入”评级，目标价由42.3港元降至38.7港元。该行预计公司自2025年起可持续获得盈利，纯利有望增至4.52亿美元，但2026年至2027年纯利预测分别下调55.6%及39.5%。

　　和黄医药管理层称，公司出售上海和黄药业的时间表符合计划，估计交易将在今年首季完成。管理层称，今次放售预计将录得投资收益4.77亿美元，而所得的现金将有助公司专注在创新疗法的研发，特别是在抗体靶向偶联药物（ATTC）平台。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.